Key facts
- This page summarizes Opaleye Management Inc.'s Form 4 filing for Protara Therapeutics, Inc. (TARA).
- 4 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 12 Sep 2024, 20:20.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Sale
Sale
Sale
Sale
Additional SEC filing notes
Footnote F1
Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund.
Footnote F2
Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account.
Footnote F3
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.70-$1.74 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.
Footnote F4
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.70-$1.75 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.